Breast Cancer Clinical Trial
— VCC0910Official title:
Impact of Weight Loss Interventions for Overweight Breast Cancer Survivors
Verified date | January 2013 |
Source | University of Vermont |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
Obesity is an epidemic and the majority of breast cancer survivors are overweight or obese.
The American Cancer Society has called for weight loss treatment to be standard of care for
overweight women with breast cancer. During therapy women with breast cancer often gain
weight and lose lean muscle mass. Overweight breast cancer survivors are more likely to have
their cancer come back. The reason why overweight breast cancer survivors are more likely to
re-occur has not been well studied, but changes in how insulin works may contribute.
Overweight survivors are also at risk for the other chronic diseases associated with
obesity. Fortunately, weight losses of as little as 5-7% of baseline body weight can improve
risk of chronic disease. An effective behaviorally-based, lifestyle intervention delivered
via the internet has been developed at the University of Vermont. This successful
intervention has not been tested among breast cancer survivors. Given that women tend to
lose muscle mass during cancer therapy the addition of a resistance training component to
the weight loss intervention may be important. Therefore the overall goal of this project is
to pilot test a proven distantly- delivered behavioral weight loss intervention among
overweight breast cancer survivors and to evaluate whether a resistance program results in
improvements in lean body mass, while studying how both interventions change insulin
sensitivity.
Specifically, this project is a randomized, controlled clinical trial designed to test the
effectiveness and acceptability of a 6-month behavioral weight loss intervention with and
without resistance training. Participants will be randomized to one of two groups: 1)
behavioral weight control treatment via the Internet; or 2) behavioral weight control
treatment via the Internet plus a resistance training program. Women eligible to participate
include overweight breast cancer survivors who are age 50 or older and 6-36 months past
receiving chemotherapy. Assessments will be conducted at baseline and six months and will
include measures of body weight, muscle mass, adherence to treatment, and insulin
sensitivity.
Status | Completed |
Enrollment | 72 |
Est. completion date | January 2012 |
Est. primary completion date | January 2012 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 40 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Post-menopausal (last period 12 mos prior to study enrollment or oophorectomy) - Age 40-65 - DCIS, Stage I, II, III Breast Cancer - BMI between 27-50 - Completed chemotherapy to treat early stage breast cancer (Stage I-III) no less then 6 months and no more than 48 months from start of study or for specific aim 3 Diagnosis of DCIS or Stage I breast cancer who did not receive chemotherapy. Exclusion Criteria: - Participant can not have a psychotic or central nervous system impairment that would limit compliance with study requirements - Evidence of metastatic disease - Chemotherapy for cancer other than breast cancer - Diabetes mellitus, uncontrolled hypo or hyper thyroidism, liver failure - Celiac sprue, inflammatory bowel disease - Inability to walk for exercise - Lymphedema as indicated by a 2 cm circumference difference at the elbow - weight loss in the previous 6 months of 10 lbs or greater |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Country | Name | City | State |
---|---|---|---|
United States | Vermont Cancer Center | Burlington | Vermont |
Lead Sponsor | Collaborator |
---|---|
University of Vermont | University of Vermont Medical Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Identify changes in energy balance and insulin sensitivity parameters in overweight breast cancer survivors after a behavioral weight loss intervention. | Primary outcome measures include weight, fat free mass, fat mass, total and active energy expenditure, calorie intake and oral glucose tolence test | Time frame is before & after the intervention. The intervention is 6 months. 4 groups of 10-22 women go through together. The groups start at different times. The last group starts May 2011. The last measurements will be obtained early Dec. of 2011. | No |
Primary | Determine whether the addition of resistance training to a behavioral weight loss intervention preserves muscle mass and improves weight loss or insulin sensitivity in breast cancer survivors. | Outcomes include weight, fat free mass, fat mass, strength (upper extremity and lower extremity) and oral glucose tolerence test | Time frame is before & after the intervention. The intervention is 6 months. 4 groups of 10-22 women go through together. The groups start at different times. The last group starts May 2011. The last measurements will be obtained early Dec. of 2011. | No |
Secondary | Identify differences in weight loss and energy balance between post menopausal breast cancer survivors who received chemotherapy and those who did not receive chemotherapy as part of their oncologic management. | Outcomes: weight, fat mass, Fat free mass, total and active energy expenditure, calorie intake | Time frame is before & after the intervention. The intervention is 6 months. 4 groups of 10-22 women go through together. The groups start at different times. The last group starts May 2011. The last measurements will be obtained early Dec. of 2011. | No |
Secondary | Determine differences in insulin sensitivity parameters between post menopausal breast cancer survivors who received chemotherapy and those who did not. | Oral glusoe tolerence test | Time frame is before & after the intervention. The intervention is 6 months. 4 groups of 10-22 women go through together. The groups start at different times. The last group starts May 2011. The last measurements will be obtained early Dec. of 2011. | No |
Secondary | Determine feasibility, acceptability, and safety of weight loss intervention without resistance training for breast cancer survivors. | Outcomes include compliance as determined by percent of indiviudals completing each lesson and completing the program. Saftery is assessed by identifying injury or worsening lymphedema. Acceptability is determined with a survey. | Time frame is before & after the intervention. The intervention is 6 months. 4 groups of 10-22 women go through together. The groups start at different times. The last group starts May 2011. The last measurements will be obtained early Dec. of 2011. | No |
Secondary | Assess changes in health-related quality of life after a weight loss intervention. | Outcomes include SF-36 and FACT-fatigue surveys | Time frame is before & after the intervention. The intervention is 6 months. 4 groups of 10-22 women go through together. The groups start at different times. The last group starts May 2011. The last measurements will be obtained early Dec. of 2011. | No |
Secondary | Determine feasibility, acceptability, and safety of weight loss intervention with resistance training for breast cancer survivors. | Outcomes include compliance as determined by percent of indiviudals completing each lesson and completing the program. Saftery is assessed by identifying injury or worsening lymphedema. Acceptability is determined with a survey. | Time frame is before & after the intervention. The intervention is 6 months. 4 groups of 10-22 women go through together. The groups start at different times. The last group starts May 2011. The last measurements will be obtained early Dec. of 2011. | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A |